Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133314) titled 'Study on Efficacy Evaluation of ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders' on Sept. 24.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Second Affiliated Hospital of the Army Medical University
Condition:
Neuromyelitis Optica Spectrum Disorders
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-30
Target Sample Size: experimental group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=345086
Published by HT Digital Content Services with permission from Health D...